VCAM-1-based visualisation is yet to be explored in the context of CRC, but the promise of anti-VCAM-1 antibodies and VCAM-1-conjugated systems in other cancer models implies the likelihood of favourable outcomes for colorectal tumour visualisation [104, 111, 112]. This evidence concerns the gene VCAM1 and cancer.